Ahn-Gook Pharmaceutical Co., Ltd.

KOSDAQ:A001540 Stock Report

Market Cap: ₩78.8b

Ahn-Gook Pharmaceutical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Ahn-Gook Pharmaceutical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth31.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Statutory Earnings May Not Be The Best Way To Understand Ahn-Gook Pharmaceutical's (KOSDAQ:001540) True Position

Aug 26
Statutory Earnings May Not Be The Best Way To Understand Ahn-Gook Pharmaceutical's (KOSDAQ:001540) True Position

Pinning Down Ahn-Gook Pharmaceutical Co., Ltd.'s (KOSDAQ:001540) P/E Is Difficult Right Now

Aug 13
Pinning Down Ahn-Gook Pharmaceutical Co., Ltd.'s (KOSDAQ:001540) P/E Is Difficult Right Now

Are Dividend Investors Making A Mistake With Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?

Apr 02
Are Dividend Investors Making A Mistake With Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?

Ahn-Gook Pharmaceutical (KOSDAQ:001540) Shareholders Booked A 29% Gain In The Last Year

Mar 07
Ahn-Gook Pharmaceutical (KOSDAQ:001540) Shareholders Booked A 29% Gain In The Last Year

Is Ahn-Gook Pharmaceutical (KOSDAQ:001540) Using Too Much Debt?

Feb 14
Is Ahn-Gook Pharmaceutical (KOSDAQ:001540) Using Too Much Debt?

Do Insiders Own Lots Of Shares In Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?

Jan 19
Do Insiders Own Lots Of Shares In Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?

Dividend Investors: Don't Be Too Quick To Buy Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Upcoming Dividend

Dec 24
Dividend Investors: Don't Be Too Quick To Buy Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Upcoming Dividend

A Look At The Fair Value Of Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)

Dec 10
A Look At The Fair Value Of Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)

Key Things To Consider Before Buying Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Dividend

Nov 18
Key Things To Consider Before Buying Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Dividend

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ahn-Gook Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A001540 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024264,63614,281-69,9557,359N/A
6/30/2024252,48015,349-84,230-10,239N/A
3/31/2024244,2236,406-85,562-16,249N/A
12/31/2023233,6761,290-7,511-1,328N/A
9/30/2023226,1864,581-10,356-4,583N/A
6/30/2023224,2197,8013,7929,035N/A
3/31/2023213,4148,2982,9057,430N/A
12/31/2022205,3896,875-1,8781,788N/A
9/30/2022195,7409,4712,3315,745N/A
6/30/2022182,7607,005-6923,063N/A
3/31/2022175,1634,077-1,8743,319N/A
12/31/2021163,5343,939-3,5911,472N/A
9/30/2021149,1371,391-26,212-698N/A
6/30/2021143,734242-29,439-3,761N/A
3/31/2021141,126-2,505-20,8923,766N/A
12/31/2020143,364-1,315-13,28411,190N/A
9/30/2020156,318-1,0036,18410,332N/A
6/30/2020160,05921521,59824,970N/A
3/31/2020158,8703,33914,30617,727N/A
12/31/2019155,8522,53618,34022,078N/A
9/30/2019167,3927,41617,78721,312N/A
6/30/2019173,0648,524-2,0311,395N/A
3/31/2019179,16612,862-1,6961,748N/A
12/31/2018185,74613,220-4,154-1,201N/A
9/30/2018177,6637,1116,97411,493N/A
6/30/2018177,6018,641N/A17,725N/A
3/31/2018179,5568,209N/A16,010N/A
12/31/2017183,6008,159N/A17,464N/A
9/30/2017182,0329,839N/A3,862N/A
6/30/2017179,0485,884N/A9,188N/A
3/31/2017176,1782,700N/A13,122N/A
12/31/2016174,0021,715N/A12,622N/A
9/30/2016183,923-185N/A21,903N/A
6/30/2016188,1943,025N/A20,365N/A
3/31/2016195,8717,926N/A26,472N/A
12/31/2015197,7369,364N/A19,106N/A
9/30/2015185,5694,360N/A10,633N/A
6/30/2015181,9733,171N/A9,681N/A
3/31/2015173,7841,123N/A546N/A
12/31/2014167,936-784N/A1,286N/A
9/30/2014161,7037,562N/A7,837N/A
6/30/2014154,3806,775N/A2,261N/A
3/31/2014152,9454,308N/A290N/A
12/31/2013153,9726,767N/A3,642N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A001540's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if A001540's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A001540's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A001540's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A001540's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A001540's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y